Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment

Next Previous
Trial Profile

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibezapolstat (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acurx Pharmaceuticals

Most Recent Events

  • 28 Oct 2025 According to an Acurx Pharmaceuticals media release, company announced data from this trial in a presentation was given by Michael Silverman, MD, FACP, at the Infectious Diseases Society of America (IDSA) IDWeek 2025 Scientific Conference held on October 19-22, 2025 in Atlanta, GA.
  • 30 Sep 2025 According to an Acurx Pharmaceuticals media release, company announced that both the EMA and the FDA are aligned with its clinical trial program in the adult population along with clearly defined requirements for the regulatory pathway to an EU MAA and a U.S. NDA.
  • 17 Jun 2025 According to an Acurx Pharmaceuticals media release, Company announced the publication of results in Lancet Microbe of its Phase 2b clinical study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top